Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $54 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.8%

Neg 0% Neu 89.8% Pos 0%

Cantor Fitzgerald analyst Carter Gould reiterates Bristol-Myers Squibb (NYSE:BMY) with a Neutral and maintains $54 price target.